SHAREHOLDER ALERT: Levi & Korsinsky, LLP Notifies Shareholders of Ontrak, Inc. of a Class Action Lawsuit and a Lead Plaintiff Deadline of May 3, 2021
Wells Fargo: 2 Strong Stocks With Upward Potential Above 70%
Wells Fargo analysts have scrutinized the market, or specifically the winners and losers of current market conditions. In a recent release, senior equity analyst Chris Harvey writes, “The risk and outperformance of small caps have made this stock market a haven for stock pickers.” Obviously, Harvey sees that small-cap stocks are doing well right now and are doing well for investors numerous options are available to choose from. While small caps are generally a riskier investment, one distinct advantage over bigger names is the potential for higher returns. This is where the risk / reward paradigm comes into play. Following Harvey’s tip, the company has made a number of recommendations and found small-cap stocks on the cusp of growth that promise a return of 70% or more for the coming year. We ran two of them through the TipRanks database to see what other Wall Street analysts were up to. Ping Identity Holding (PING) Based on the technology industry, Wells Fargo’s first pick is Ping Identity Holding Corp, which specializes in identity management. The company offers a range of products that customers can use to control login and access to networks and databases. While Ping Identity has been in business for nearly 20 years, it has only been a public company for a year and a half. In the company’s most recent quarterly report for the fourth quarter of 2010, Ping reported mixed results, and immediately posted a 20% decline in price. The EPS was a net loss of 4 cents per share. Revenue was down 7% year-over-year to $ 63.2 million, but increased 5.5% sequentially, marking the second highest quarterly revenue the company has had since going public. For the full year, total revenue was $ 243.6 million, driven by a 15% increase in annual recurring revenue (ARR) year over year, which hit $ 259.1 million. The company saw a 34% increase in customers with an ARR of more than $ 1 million, a solid win on one key metric. Wells Fargo analyst Philip Winslow was particularly impressed with the ARR gain. “Ping reported solid fourth quarter results, with ARR exceeding expectations. The 15% year-over-year ARR growth was above consensus estimates of $ 256.1 million due to continued adoption of SaaS solutions, which accelerated more than expected and accounted for + 15% of total ARR, ” wrote the 5-star analyst. Winslow added, “The company is seeing continued signs of pent-up demand as customers phased out their purchases as projects previously suspended from COVID budget pressures emerge in the pipeline and companies modernize legacy systems whose flaws are exposed been the past year. “To this end, Winslow rates PING as overweight (i.e. buy) and has a target price of $ 40, indicating upside potential of 76% over the next 12 months. (To see Winslow’s track record, click here.) Winslow is not an outlier in his bullish stance, but there is some divide on Wall Street over ping. The analysts’ consensus view is a moderate buy based on a dozen ratings that consisted of 7 buys and 5 holds The shares are priced at $ 22.59 and their average target price of $ 33.71 indicates a year-long share Upward movement of 49%. (See PING stock analysis on TipRanks.) Sangamo Therapeutics (SGMO) Let’s shift gears and take a look at the life science sector. Sangamo is a biotechnology company focused on developing genomic therapies to treat genetic diseases. The company’s pipeline includes 17 different programs at various stages of development that target a range of diseases, including IBD, beta thalassemia, sickle cell disease and hemophilia A. Back in December, the company reported an update on its ongoing collaboration with Pfizer on Giroctocogene fitelparvovec. This is a gene therapy product that is being developed to treat haemophilia A. Follow-up data from the Phase 1/2 Alta study indicated that the drug was well tolerated and safe in the small cohort of patients tested. Giroctocogene fitelparvovec is now starting the patient dosage phase of the phase 3 AFFINE study. In February, Sangamo reported that it had entered into a global partnership with Biogen to develop and commercialize new therapies for gene regulation. The therapies under consideration target Alzheimer’s, Parkinson’s and other neurological diseases. The bulls include Wells Fargo analyst Yanan Zhu, who wrote of the bigger picture: “Overall, we continue to see significant upside in the company’s genomic drug pipeline programs and platforms, particularly the regulatory T (Treg) cell therapy platform may target a wide range of autoimmune diseases and the ZFP-TF gene regulatory platform, which may target certain difficult-to-target neurological indications… ”In light of these comments, Zhu reiterates the company’s overweight (i.e. buy) rating on the stock and set up target price $ 29, suggesting a robust upward move of 158%. (To see Zhu’s track record, click here.) Overall, SGMO has shown optimism and caution about the consensus view among sell-side analysts. Out of 5 analysts surveyed over the past 3 months, 2 are bullish about the stock while 3 continue to fail. The bulls have the edge, however, as the average price target is $ 19.40 and indicates a 72% uptrend. (See SGMO stock analysis on TipRanks.) To find great ideas for trading stocks at attractive valuations, visit TipRanks’ Best Stocks to Buy, ‘a newly launched tool that brings together all of TipRanks’ stock insights. Disclaimer: The opinions expressed in this article are solely those of the presented analysts. The content is intended to be used for informational purposes only. It is very important that you do your own analysis before making any investment.